ANDA 40827, held by Hospira. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 40827 (A-Methapred), held by Hospira, was first approved by FDA on Nov 25, 2008, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| A-MethapredEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Jan 22, 2016 | Supplement 5Labeling | Approved | None posted |
| Jan 22, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 25, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters